ArticleThe Korean journal of internal medicine2026
Prognostic analysis according to adjuvant chemotherapy and anti-HER2 therapy following surgery in T1a/b HER2-positive breast cancer.
Article in The Korean journal of internal medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimsThe optimal adjuvant chemotherapy and anti-human epidermal growth factor receptor 2 (HER2) therapy regimen following surgery for T1a/b HER2-positive breast cancer remains debatable.
methodsIn this single-center retrospective analysis, we examined the postoperative treatment strategies for patients diagnosed with T1a/b node-negative HER2-positive breast cancer. Invasive breast cancer-free survival (IBCFS), invasive disease-free survival, and overall survival (OS) were compared between patients who received chemotherapy only, chemotherapy plus anti-HER2 therapy, and neither adjuvant treatment.
resultsThe analysis included 165 patients, with a median follow-up duration of 98.4 (25.8-238.5) months. Patients who did not receive any adjuvant therapy had a 15-year IBCFS rate of 86.9%, and those who received only chemotherapy exhibited a rate of 77.6%. Conversely, those who received both trastuzumab and chemotherapy had the highest 15-year IBCFS rate of 97.4%, although the difference between the treatment groups was not statistically significant (p = 0.492). Among patients with T1a tumors, chemotherapy plus anti-HER2 therapy showed the most favorable long-term IBCFS, with a 15-year rate of 100%, compared with 57.5% in the chemotherapy-only group and 79.8% in the no-treatment group (p = 0.363). The 15-year OS rate was 100% in both chemotherapy-containing treatment groups, compared with 90.4% in the no-treatment group (p = 0.068).
conclusionIn this retrospective cohort of patients with HER2-positive T1a/bN0 breast cancer, anti-HER2-containing adjuvant treatment was associated with numerically favorable long-term outcomes, particularly among those with T1a tumors. Given the retrospective study design and limited number of events, these findings should be interpreted cautiously.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.